152 results
8-K
EX-99.2
VNDA
Vanda Pharmaceuticals Inc
17 Apr 24
Entry into a Material Definitive Agreement
5:19pm
balance and long-term future growth prospects. Vanda has established a resilient business with a diverse product set, a history of top-line growth
8-K
EX-99.1
VNDA
Vanda Pharmaceuticals Inc
17 Apr 24
Entry into a Material Definitive Agreement
5:19pm
robust clinical development pipeline, expanding commercial presence, significant, cash balance and long-term future growth prospects.
The Rights Plan
8-K
EX-99.1
VNDA
Vanda Pharmaceuticals Inc
3 Apr 24
Vanda Pharmaceuticals’ Fanapt® (iloperidone) Receives U.S. FDA Approval
4:32pm
financial position. We remain focused on providing critical medicines to patients across the world while creating sustainable, long-term value.”
References
S-8
EX-1.01
qh7zcw8s3h
8 Jun 23
Registration of securities for employees
4:46pm
8-K
EX-99.1
92esl3k8j
2 Nov 22
Vanda Pharmaceuticals Reports Third Quarter 2022 Financial Results
4:08pm
S-8
EX-10.1
bowunill
17 Jun 22
Registration of securities for employees
4:16pm
8-K
EX-99.1
7i2c 1pss53zx
3 Nov 21
Vanda Pharmaceuticals Reports Third Quarter 2021 Financial Results
4:08pm